Signs of progress against the superbugs, but not yet at the scale needed
A core group of pharmaceutical companies are making progress in tackling the spread of antimicrobial resistance, new findings from the 2020 Antimicrobial Resistance Benchmark indicate. However, although a few companies are expanding their efforts, change is not happening at the scale needed to radically impact the threat from drug resistance.
The 2020 Antimicrobial Resistance Benchmark, published today, finds that more companies are moving to discourage the overselling of their antibiotics and antifungal medicines to doctors and other healthcare professionals. Most companies have a strategy to prevent antibacterial residue being released in factory wastewaters. Furthermore, pharmaceutical companies are sharing more data on where drug resistance is emerging.
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!